MP14-15 INCREASE IN THE INCIDENCE OF ADVANCED PROSTATE CANCER IN THE UNITED STATES

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Jonathan Shoag ◽  
Art Sedrakyan ◽  
Joshua Halpern ◽  
Wei-Chun Hsu ◽  
Jim Hu
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Advanced Prostate Cancer ◽  
The United States

MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Thomas Jang ◽  
Neal Patel ◽  
Shunhua Shen ◽  
Michael Karellas ◽  
Robert DiPaola ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Advanced Prostate Cancer ◽  
The United States ◽  
Initial Therapy ◽  
Factors Associated

scholarly journals Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.

2017 ◽  
Vol 35 (8_suppl) ◽  
pp. 35-35
Author(s):  
Megan Veresh Caram ◽  
Tudor Borza ◽  
Hye-Sung Min ◽  
Jennifer J. Griggs ◽  
David Christopher Miller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Regional Variation ◽  
Advanced Prostate Cancer ◽  
Medicare Part D ◽  
The United States ◽  
Medicare Part ◽  
Part D ◽  
Hospital Referral ◽  
Early National

35 Background: Abiraterone and enzalutamide are oral medications approved by the Food & Drug Administration in 2011 and 2012 to treat men with advanced castration-resistant prostate cancer. Most men with advanced prostate cancer are over age 65 and thus eligible for Medicare Part D. We conducted a study to better understand the early dissemination of these drugs across the United States using national Medicare Part D data. Methods: We evaluated the number of prescriptions for abiraterone and enzalutamide by provider specialty and hospital referral region (HRR) using Medicare Part D and Dartmouth Atlas data. We categorized HRRs by abiraterone and enzalutamide prescriptions, adjusted for prostate cancer incidence, and examined factors associated with regional variation using multilevel regression models. Results: Among all providers who wrote prescriptions for abiraterone or enzalutamide in 2013 (n=2121), 87.5% were medical oncologists, 3.3% urologists, and 9.2% were listed as other provider specialties. Among those who prescribed either drug, 5% of providers were responsible for 75% of the claims for abiraterone, and 7% were responsible for 75% of the claims for enzalutamide. Some HRRs demonstrated low-prescribing rates despite average medical oncology and urology physician workforce density. Conclusions: The majority of prescriptions written for abiraterone and enzalutamide through Medicare Part D in 2013 were written by a minority of providers with marked regional variation across the United States. Better understanding the early national dissemination of these effective but expensive drugs can help inform strategies to optimize introduction of new, evidence-based advanced prostate cancer treatments.

Therapeutic Patterns and Barriers to the Treatment of Advanced Prostate Cancer: A Survey of Academic and Community Urologists in the United States

2018 ◽  
Vol 5 (1) ◽  
pp. 15-23
Author(s):  
Edouard J. Trabulsi ◽  
Patricia Jassak ◽  
Hong Tang ◽  
Sharon Hwang ◽  
Gregory D. Salinas
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Advanced Prostate Cancer ◽  
The United States

scholarly journals Prostate-specific Antigen Screening and Recent Increases in Advanced Prostate Cancer

2020 ◽  
Author(s):  
Yaw A Nyame ◽  
Roman Gulati ◽  
Alex Tsodikov ◽  
John L Gore ◽  
Ruth Etzioni
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Prostate Specific Antigen ◽  
Advanced Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
The United States ◽  
Models Of Disease ◽  
Screening And Diagnosis

Abstract Recent studies show decreasing prostate-specific antigen utilization and increasing incidence of metastatic prostate cancer in the United States after national recommendations against screening in 2012. Yet whether the increasing incidence of metastatic prostate cancer is consistent in magnitude with the expected impact of decreased screening is unknown. We compared observed incidence of metastatic prostate cancer from the Surveillance, Epidemiology, and End Results program and published effects of continued historical screening and discontinued screening starting in 2013 projected by two models of disease natural history, screening, and diagnosis. The observed rate of new metastatic prostate cancer cases in 2017 was 44%-60% of the projected increase under discontinued screening relative to continued screening. Thus, the observed increase in incident metastatic prostate cancer is consistent with the expected impact of reduced screening. Although this comparison does not establish a causal relationship, it highlights the plausible role of decreased screening in the observed trend.

scholarly journals Racial Differences in Incident Genitourinary Cancer Cases Captured in the National Cancer Database

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 671
Author(s):  
Dylan T. Wolff ◽  
Thomas F. Monaghan ◽  
Danielle J. Gordon ◽  
Kyle P. Michelson ◽  
Tashzna Jones ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Bladder Cancer ◽  
Kidney Cancer ◽  
The United States ◽  
Coverage Rate ◽  
National Cancer Database ◽  
Genitourinary Cancer ◽  
Coverage Rates ◽  
Capture Rates

Background and Objectives: The National Cancer Database (NCDB) captures nearly 70% of all new cancer diagnoses in the United States, but there exists significant variation in this capture rate based on primary tumor location and other patient demographic factors. Prostate cancer has the lowest coverage rate of all major cancers, and other genitourinary malignancies likewise fall below the average NCDB case coverage rate. We aimed to explore NCDB coverage rates for patients with genitourinary cancers as a function of race. Materials and Methods: We compared the incidence of cancer cases in the NCDB with contemporary United States Cancer Statistics data. Results: Across all malignancies, American Indian/Alaskan Natives subjects demonstrated the lowest capture rates, and Asian/Pacific Islander subjects exhibited the second-lowest capture rates. Between White and Black subjects, capture rates were significantly higher for White subjects overall and for prostate cancer and kidney cancer in White males, but significantly higher for bladder cancer in Black versus White females. No significant differences were observed in coverage rates for kidney cancer in females, bladder cancer in males, penile cancer, or testicular cancer in White versus Black patients. Conclusions: Differential access to Commission on Cancer-accredited treatment facilities for racial minorities with genitourinary cancer constitutes a unique avenue for health equity research.

Sign in / Sign up

Export Citation Format

Share Document